| 22.68 -0.77 (-3.28%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.05  |
1-year : | 32.37 |
| Resists | First : | 25.73 |
Second : | 27.71 |
| Pivot price | 24.79 |
|||
| Supports | First : | 22.52 |
Second : | 18.73 |
| MAs | MA(5) : | 23.42 |
MA(20) : | 24.83 |
| MA(100) : | 23.24  |
MA(250) : | 17.97 |
|
| MACD | MACD : | -0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 15.4 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 27.71 | Low : | 8.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELAN ] has closed above bottom band by 8.3%. Bollinger Bands are 104.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.47 - 23.66 | 23.66 - 23.79 |
| Low: | 22.13 - 22.34 | 22.34 - 22.48 |
| Close: | 22.41 - 22.73 | 22.73 - 22.95 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Wed, 11 Mar 2026
ELAN: Raised 2026 innovation revenue targets and margin expansion driven by robust product launches - TradingView
Wed, 11 Mar 2026
UBS maintains Buy on ELAN (Elanco Animal Health Incorporated) March 2026 - Meyka
Tue, 10 Mar 2026
ELAN: Innovation and strong execution drive growth and margin expansion across all business segments - TradingView
Sat, 07 Mar 2026
Elanco Animal Health (ELAN) Price Target Increased by 14.11% to 22.35 - MSN
Tue, 03 Mar 2026
Royce & Associates LP Buys 105,632 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Tue, 24 Feb 2026
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 497 (M) |
| Shares Float | 493 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 109.7 (%) |
| Shares Short | 18,410 (K) |
| Shares Short P.Month | 23,120 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.17 |
| Profit Margin | -5 % |
| Operating Margin | 2.2 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | -3.7 % |
| Qtrly Rev. Growth | 12.1 % |
| Gross Profit (p.s.) | 5.2 |
| Sales Per Share | 9.47 |
| EBITDA (p.s.) | 1.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 560 (M) |
| Levered Free Cash Flow | 560 (M) |
| PE Ratio | -48.26 |
| PEG Ratio | 0 |
| Price to Book value | 1.72 |
| Price to Sales | 2.39 |
| Price to Cash Flow | 20.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|